Cost and outcomes of patients with solitary pulmonary nodules managed with PET scans

Chest

Volumn 137, Issue 1, 2010, Pages 53-59

  Barnett, Paul G ^a,c   Ananth, Lakshmi ^a   Gould, Michael K ^b,c  

^a Health Economics Resource Center   (United States)

^b VA PALO ALTO HEALTH CARE SYSTEM   (United States)

^c STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; FALSE NEGATIVE RESULT; FALSE POSITIVE RESULT; FEMALE; FOLLOW UP; HOSPITAL COST; HUMAN; HUMAN TISSUE; LUNG BIOPSY; LUNG CANCER; LUNG NODULE; MALE; MORTALITY; MULTIMODALITY CANCER THERAPY; OUTCOME ASSESSMENT; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL;

EID: 74949144121     PISSN: 00123692     EISSN: 19313543     Source Type: Journal    
DOI: 10.1378/chest.08-0529     Document Type: Article

References (32)

1. Mountain CF. Revisions in the International System for Staging Lung Cancer. Chest. 1997;111(6):1710-1717.
2. Ginsberg RJ, Rubinstein LV. Randomized trial of lobectomy versus limited resection for T1 N0 non-small cell lung cancer. Lung Cancer Study Group. Ann Thorac Surg. 1995;60: 615-622.
3. Inoue K, Sato M, Fujimura S, et al. Prognostic assessment of 1310 patients with non-small-cell lung cancer who underwent complete resection from 1980 to 1993. J Thorac Cardiovasc Surg. 1998;116(3):407-411.
4. Henschke CI, McCauley DI, Yankelevitz DF, et al. Early Lung Cancer Action Project: overall design and findings from baseline screening. Lancet. 1999;354(9173):99-105.
5. Holin SM, Dwork RE, Glaser S, Rikli AE, Stocklen JB. Solitary pulmonary nodules found in a community-wide chest roentgenographic survey; a five-year follow-up study. Am Rev Tuberc. 1959;79(4):427-439.
6. Swensen SJ, Morin RL, Schueler BA, et al. Solitary pulmonary nodule: CT evaluation of enhancement with iodinated contrast material-a preliminary report. Radiology. 1992; 182(2):343-347.
7. Khan A, Herman PG, Vorwerk P, Stevens P, Rojas KA, Graver M. Solitary pulmonary nodules: comparison of classification with standard, thin-section, and reference phantom CT. Radiology. 1991;179(2):477-481.
8. Gould MK, Fletcher J, Iannettoni MD, et al; American College of Chest Physicians. Evaluation of patients with pulmonary nodules: when is it lung cancer?: ACCP evidence-based clinical practice guidelines (2nd edition). Chest. 2007;132(3 suppl):108S-130S.
9. Berger M, Gould MK, Barnett PG. The cost of positron emission tomography in six United States Veterans Affairs hospitals and two academic medical centers. AJR Am J Roentgenol. 2003;181(2):359-365.
10. Gould MK, Sanders GD, Barnett PG, et al. Cost-effectiveness of alternative management strategies for patients with solitary pulmonary nodules. Ann Intern Med. 2003;138(9):724-735.
11. Lejeune C, Al Zahouri K, Woronoff-Lemsi MC, et al. Use of a decision analysis model to assess the medicoeconomic implications of FDG PET imaging in diagnosing a solitary pulmonary nodule. Eur J Health Econ. 2005;6(3):203-214.
12. Gugiatti A, Grimaldi A, Rossetti C, et al. Economic analyses on the use of positron emission tomography for the work-up of solitary pulmonary nodules and for staging patients with non-small-cell-lung-cancer in Italy. Q J Nucl Med Mol Imaging. 2004;48(1):49-61.
13. Tsushima Y, Endo K. Analysis models to assess cost effectiveness of the four strategies for the work-up of solitary pulmonary nodules. Med Sci Monit. 2004;10(5):MT65-MT72.
14. Keith CJ, Miles KA, Griffiths MR, Wong D, Pitman AG, Hicks RJ. Solitary pulmonary nodules: accuracy and cost-effectiveness of sodium iodide FDG-PET using Australian data. Eur J Nucl Med Mol Imaging. 2002;29(8):1016-1023.
15. Comber LA, Keith CJ, Griffiths M, Miles KA. Solitary pulmonary nodules: impact of quantitative contrast-enhanced CT on the cost-effectiveness of FDG-PET. Clin Radiol. 2003;58(9):706-711.
16. Wolstenholme JL, Whynes DK. The hospital costs of treating lung cancer in the United Kingdom. Br J Cancer. 1999;80 (1-2):215-218.
17. Dedes KJ, Szucs TD, Bodis S, et al. Management and costs of treating lung cancer patients in a university hospital. Pharmacoeconomics. 2004;22(7):435-444.
18. Braud AC, Lévy-Piedbois C, Piedbois P, et al. Direct treatment costs for patients with lung cancer from first recurrence to death in france. Pharmacoeconomics. 2003;21(9):671-679.
19. Riley GF, Potosky AL, Lubitz JD, Kessler LG. Medicare payments from diagnosis to death for elderly cancer patients by stage at diagnosis. Med Care. 1995;33(8):828-841.
20. Hillner BE, McDonald MK, Desch CE, et al. Costs of care associated with non-small-cell lung cancer in a commercially insured cohort. J Clin Oncol. 1998;16(4):1420-1424.
21. Kutikova L, Bowman L, Chang S, Long SR, Obasaju C, Crown WH. The economic burden of lung cancer and the associated costs of treatment failure in the United States. Lung Cancer. 2005;50(2):143-154.
22. Goodwin PJ, Shepherd FA. Economic issues in lung cancer: a review. J Clin Oncol. 1998;16(12):3900-3912.
23. 18F-FDG PET and CT in the characterization of solitary pulmonary nodules. J Nucl Med. 2008;49(2):179-185.
24. Marom EM, Sarvis S, Herndon JE II, Patz EF Jr. T1 lung cancers: sensitivity of diagnosis with fluorodeoxyglucose PET. Radiology. 2002;223(2):453-459.
25. Cheran SK, Nielsen ND, Patz EF Jr. False-negative findings for primary lung tumors on FDG positron emission tomography: staging and prognostic implications. AJR Am J Roentgenol. 2004;182(5):1129-1132.
26. Kymes SM, Lee K, Fletcher JW; SNAP (CSP 027) Study Group. Assessing diagnostic accuracy and the clinical value of positron emission tomography imaging in patients with solitary pulmonary nodules (SNAP). Clin Trials. 2006;3(1):31-42.
27. Wagner TH, Chen S, Barnett PG. Using average cost methods to estimate encounter-level costs for medical-surgical stays in the VA. Med Care Res Rev. 2003;60(3 suppl):15S-36S.
28. Phibbs CS, Bhandari A, Yu W, Barnett PG. Estimating the costs of VA ambulatory care. Med Care Res Rev. 2003; 60(3 suppl):54S-73S.
29. Smith MW, Joseph GJ. Pharmacy data in the VA health care system. Med Care Res Rev. 2003;60(3 suppl):92S-123S.
30. Barnett PG, Linn P, Wagner TH. Estimating the cost of cardiac care provided by the hospitals of the U.S. Department of Veterans Affairs. In: Weintraub W, ed. Cardiovascular Health Care Economics. Totowa, NJ: Humana Press; 2002:15-29.
31. Fisher SG, Weber L, Goldberg J, Davis F. Mortality ascertainment in the veteran population: alternatives to the National Death Index. Am J Epidemiol. 1995;141(3):242-250.
32. Oliver E, Killen J, Kiebert G, et al. Treatment pathways, resource use and costs in the management of small cell lung cancer. Thorax. 2001;56(10):785-790.